Analysis of common eligibility criteria of randomized controlled trials in newly diagnosed multiple myeloma patients and extrapolating outcomes JJ Shah, R Abonour, C Gasparetto, JW Hardin, K Toomey, M Narang, ... Clinical Lymphoma Myeloma and Leukemia 17 (9), 575-583. e2, 2017 | 87 | 2017 |
Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study H Yimer, J Melear, E Faber, WI Bensinger, JM Burke, M Narang, ... British journal of haematology 185 (3), 492-502, 2019 | 61 | 2019 |
Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA® registry DL Grinblatt, MA Sekeres, RS Komrokji, AS Swern, KA Sullivan, M Narang Leukemia & lymphoma 56 (4), 887-895, 2015 | 49 | 2015 |
Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry R Abonour, L Wagner, BGM Durie, S Jagannath, M Narang, HR Terebelo, ... Annals of Hematology 97, 2425-2436, 2018 | 40 | 2018 |
Recognition of early mortality in multiple myeloma by a prediction matrix H Terebelo, S Srinivasan, M Narang, R Abonour, C Gasparetto, K Toomey, ... American journal of hematology 92 (9), 915-923, 2017 | 39 | 2017 |
Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM S Jagannath, R Abonour, BGM Durie, M Narang, HR Terebelo, ... Blood advances 2 (13), 1608-1615, 2018 | 33 | 2018 |
Refractory autoimmune thrombocytopenic purpura: responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab) M Narang, JA Penner, D Williams American journal of hematology 74 (4), 263-267, 2003 | 32 | 2003 |
Heterogeneity of second-line treatment for patients with multiple myeloma in the connect MM registry (2010-2016) S Jagannath, R Abonour, BGM Durie, C Gasparetto, JW Hardin, ... Clinical Lymphoma Myeloma and Leukemia 18 (7), 480-485. e3, 2018 | 31 | 2018 |
Connect MM®–the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide RM Rifkin, R Abonour, JJ Shah, J Mehta, M Narang, H Terebelo, ... Leukemia & Lymphoma 57 (9), 2228-2231, 2016 | 28 | 2016 |
Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis S Ailawadhi, S Jagannath, HC Lee, M Narang, RM Rifkin, HR Terebelo, ... Cancer 126 (19), 4332-4340, 2020 | 22 | 2020 |
Development of a prognostic model for overall survival in multiple myeloma using the Connect® MM Patient Registry HR Terebelo, R Abonour, CJ Gasparetto, K Toomey, BGM Durie, ... British Journal of Haematology 187 (5), 602-614, 2019 | 19 | 2019 |
A study comparing dosing regimens and efficacy of subcutaneous to intravenous azacitidine (AZA) for the treatment of myelodysplastic syndromes (MDS). MA Sekeres, JP Maciejewski, DW Donley, DL Grinblatt, M Narang, ... Blood 114 (22), 3797, 2009 | 19 | 2009 |
Treatment outcomes and health care resource utilization in patients with newly diagnosed multiple myeloma receiving lenalidomide-only maintenance, any maintenance, or no … RM Rifkin, S Jagannath, BGM Durie, M Narang, HR Terebelo, ... Clinical Therapeutics 40 (7), 1193-1202. e1, 2018 | 18 | 2018 |
Connect MM Registry as a national reference for United States multiple myeloma patients S Ailawadhi, S Jagannath, M Narang, RM Rifkin, HR Terebelo, K Toomey, ... Cancer medicine 9 (1), 35-42, 2020 | 17 | 2020 |
Treatment journeys of patients with newly diagnosed multiple myeloma (NDMM): results from the Connect MM Registry S Jagannath, RM Rifkin, CJ Gasparetto, K Toomey, BGM Durie, ... Clinical Lymphoma Myeloma and Leukemia 20 (5), 272-276, 2020 | 16 | 2020 |
Lyra: a phase 2 study of daratumumab (Dara) plus cyclophosphamide, bortezomib, and dexamethasone (Cybord) in newly diagnosed and relapsed patients (Pts) with multiple myeloma (MM) H Yimer, J Melear, E Faber, W Bensinger, JM Burke, M Narang, ... Blood 132, 152, 2018 | 16 | 2018 |
Effect of t (11; 14) abnormality on outcomes of patients with newly diagnosed multiple myeloma in the connect MM registry C Gasparetto, S Jagannath, RM Rifkin, BGM Durie, M Narang, ... Clinical Lymphoma Myeloma and Leukemia 22 (3), 149-157, 2022 | 15 | 2022 |
Health-related quality of life of patients with newly diagnosed multiple myeloma receiving any or lenalidomide maintenance after autologous stem cell transplant in the Connect … R Abonour, BGM Durie, S Jagannath, JJ Shah, M Narang, HR Terebelo, ... Blood 128 (22), 537, 2016 | 15 | 2016 |
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study H Yimer, J Melear, E Faber, WI Bensinger, JM Burke, M Narang, ... Leukemia & lymphoma 63 (10), 2383-2392, 2022 | 11 | 2022 |
Treatment of Patients with Low-Risk Myelodysplastic Syndromes Receiving Azacitidine Who Are Enrolled in AVIDA, a Longitudinal Patient Registry. DL Grinblatt, M Narang, JM Malone III, DA Sweet, TS Dunne, KA Sullivan Blood 112 (11), 1646, 2008 | 11 | 2008 |